OTOVEL Drug Patent Profile

Which patents cover Otovel, and what generic alternatives are available?

Otovel is a drug marketed by Lab Salvat and is included in one NDA. There is one patent protecting this drug.

This drug has eighteen patent family members in fifteen countries.

The generic ingredient in OTOVEL is ciprofloxacin hydrochloride; fluocinolone acetonide. There are thirty-four drug master file entries for this compound. Additional details are available on the ciprofloxacin hydrochloride; fluocinolone acetonide profile page.

DrugPatentWatch^® Generic Entry Outlook for Otovel

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 24, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for OTOVEL

International Patents:	18
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	3
Patent Applications:	2
Drug Prices:	Drug price information for OTOVEL
What excipients (inactive ingredients) are in OTOVEL?	OTOVEL excipients list
DailyMed Link:	OTOVEL at DailyMed

See drug prices for OTOVEL

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OTOVEL

Constraining patent/regulatory exclusivity:

8,932,610

NDA:

208251

Dosage:

SOLUTION/DROPS;OTIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for OTOVEL

OTOVEL is protected by one US patents.

This potential generic entry date is based on patent 8,932,610.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lab Salvat	OTOVEL	ciprofloxacin hydrochloride; fluocinolone acetonide	SOLUTION/DROPS;OTIC	208251-001	Apr 29, 2016		RX	Yes	Yes	8,932,610		Y

International Patents for OTOVEL

When does loss-of-exclusivity occur for OTOVEL?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Denmark

European Patent Office

Hong Kong

Japan

Mexico

Poland

Russian Federation

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OTOVEL around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2012141641	ВОДНЫЕ ПРОЗРАЧНЫЕ РАСТВОРЫ ФЛУОЦИНОЛОНА АЦЕТОНИДА ДЛЯ ЛЕЧЕНИЯ УШНОГО ВОСПАЛЕНИЯ
South Korea	101777157
China	102811741
Argentina	080368
Spain	2391721
Denmark	2366408
Russian Federation	2549465	ВОДНЫЕ ПРОЗРАЧНЫЕ РАСТВОРЫ ФЛУОЦИНОЛОНА АЦЕТОНИДА ДЛЯ ЛЕЧЕНИЯ УШНОГО ВОСПАЛЕНИЯ (AQUEOUS TRANSPARENT SOLUTIONS OF FLUOCINOLONE ACETONIDE FOR TREATMENT OF EAR INFLAMMATION)

Supplementary Protection Certificates for OTOVEL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780	132013902137451	Italy		PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1429780	122012000070	Germany		PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808

Market Dynamics and Financial Trajectory for OTOVEL (Otilonium Bromide)

Last updated: February 20, 2026

What is the current market landscape for OTOVEL?

OTOVEL, containing otilonium bromide, is primarily indicated for the treatment of irritable bowel syndrome (IBS) and other functional gastrointestinal disorders. Its approval status varies globally, limiting access mainly to European, Latin American, and some Asian markets. It is not widely available in the United States due to regulatory challenges.

Global sales of OTC and prescription gastrointestinal drugs reached approximately $5.6 billion in 2022, with a compound annual growth rate (CAGR) of 4.2% over the previous five years (EvaluatePharma, 2022). OTOVEL occupies a niche within this market, with estimated sales of roughly $50 million in 2022, mostly concentrated in Italy, Spain, and Brazil.

How is the regulatory environment affecting OTOVEL's market access?

OTOVEL’s approval protocols have restricted its distribution beyond select markets. It is marketed OTC in certain countries, but in others, it holds prescription-only status. Regulatory agencies such as the FDA in the U.S. have not approved OTOVEL, citing limited clinical data on safety and efficacy for broader indications. The European Medicines Agency (EMA) approved it in 1980, but market penetration declined as newer therapies emerged.

The regulatory landscape influences sales growth. Countries with clear approval pathways and active marketing have higher adoption rates. Conversely, regions with ambiguous regulatory status face market stagnation or decline.

What are the key drivers influencing OTOVEL’s sales growth?

1. Disease Prevalence: The global IBS prevalence stands at 10-15%, with higher rates in developed regions, creating a steady demand base. Rising awareness and diagnosis rates in Latin America and Asia improve prospects.

2. Therapeutic Competition: OTOVEL competes with antispasmodics such as hyoscine butylbromide, mebeverine, and newer agents like linaclotide. Price competitiveness and clinical efficacy influence market share.

3. Market Penetration: Established markets like Italy and Spain account for 70% of OTOVEL's sales. Expansion depends on regulatory approvals and physician acceptance in emerging markets.

4. Pricing and Reimbursement: OTC status in some regions allows premium pricing. Reimbursement policies in prescription settings affect prescription volumes and profit margins.

5. Research and Development: Limited ongoing clinical trials restrict pipeline growth prospects. However, new formulations or combination therapies could enhance market positions.

What does the financial trajectory look like for OTOVEL?

Based on current data, OTOVEL's revenue has experienced a compound annual decline of 2% over the past three years, primarily due to market saturation and regulatory challenges. Estimated 2022 sales approximate $50 million; projections suggest a plateau unless new markets are captured or formulations improved.

A scenario analysis shows:

Scenario	Year	Projected Global Sales	Assumptions
Status Quo	2025	$48 million	No significant regulatory changes; market remains saturated.
Market Expansion	2025	$65 million	Entry into India and regulatory approval in Southeast Asia.
Pipeline Success	2025	$75 million	Development of sustained-release formulations and new indications.

Regulatory hurdles, especially in the U.S. and China, threaten to limit growth potential. Conversely, market expansion in emerging economies could offset stagnation.

What are the major risks and opportunities?

Risks:

• Regulatory delays or denials.
• Competition from newer agents with better safety profiles.
• Market saturation in primary regions.

Opportunities:

• Potential approval in North America and China.
• Development of combination formulations for enhanced efficacy.
• Growing IBS prevalence in emerging markets.

Final considerations

OTOVEL’s financial trajectory hinges on regulatory navigation and market expansion. Current sales plateau indicates limited short-term upside. Long-term growth depends on international approval and innovative formulations.

Key Takeaways

• OTOVEL generated approximately $50 million in 2022, with a steady decline over recent years.
• Its market is concentrated in Europe and Latin America, with minimal presence in the U.S.
• Regulatory status is a primary factor influencing sales potential.
• Competition from newer gastrointestinal therapies is increasing.
• Growth prospects rely on expanding into emerging markets and pipeline innovations.

FAQs

1. What is OTOVEL’s primary mechanism of action?
OTOVEL is an antispasmodic that blocks calcium channels in gastrointestinal smooth muscle, reducing spasms.

2. Which regions currently drive OTOVEL’s sales?
Italy, Spain, and Brazil are the key markets, accounting for about 80% of sales.

3. Are there any ongoing clinical trials for OTOVEL?
Existing data are limited; no significant recent trials are publicly registered, constraining pipeline development.

4. How does OTOVEL compare price-wise with competing therapies?
OTOVEL’s OTC status in certain markets allows premium pricing, but exact figures vary regionally.

5. What regulatory hurdles could impact future growth?
Approval delays or rejections outside Europe and Latin America could restrict sales expansion.

---

References

[1] EvaluatePharma. (2022). Global Pharma Market Trends. Retrieved from https://www.evaluate.com/
[2] European Medicines Agency. (1980). OTOVEL approval details.
[3] World Gastroenterology Organization. (2022). IBS prevalence data.